Una variant patogènica de BRCA1 o BRCA2 augmenta el risc hereditari de càncer; no diagnostica càncer. Una variant de significat incert no hauria de determinar una cirurgia preventiva. Un resultat negatiu només és un veritable negatiu quan exclou una variant familiar coneguda; altrament, pot deixar sense resoldre el risc hereditari.
Conclusions principals
- Resultat positiu significa que s’ha identificat una variant patogènica o probablement patogènica; la predisposició hereditària no és un diagnòstic de càncer.
- Cinc classificacions descriuen les variants genètiques: patogèniques, probablement patogèniques, de significat incert, probablement benignes i benignes.
- Risc de BRCA1 en un estudi prospectiu de JAMA va arribar aproximadament al 72% per al càncer de mama i al 44% per al càncer d’ovari als 80 anys en dones portadores de variants patogèniques.
- Risc de BRCA2 en el mateix estudi va arribar aproximadament al 69% per al càncer de mama i al 17% per al càncer d’ovari als 80 anys; són estimacions de grup, no prediccions personals.
- Gestió de la VUS ha de basar-se en els antecedents personals i familiars, no en la variant incerta; una VUS per si sola no justifica una cirurgia preventiva.
- Resultat veritablement negatiu vol dir que el laboratori no ha trobat la variant patogènica específica ja identificada a la vostra família.
- Resultat negatiu no informatiu vol dir que les proves no han trobat cap explicació per al risc hereditari sospitat; uns antecedents familiars sòlids encara poden justificar una avaluació addicional.
- Herència familiar sol donar a cada fill d’una persona portadora d’una variant patogènica germinal de BRCA1 o BRCA2 un 50% de probabilitats d’heretar aquesta variant.
- El consell genètic ajuda a relacionar la variant exacta, la cobertura de les proves, les dues branques de la família i les opcions de cribratge o prevenció en funció de l’edat.
Què signifiquen realment els resultats d’una prova genètica de BRCA?
resultats de les proves genètiques de BRCA solen classificar-se en 3 grups pràctics: positiu, incert o negatiu. Un resultat hereditari positiu identifica una predisposició al càncer, una variant de significat incert continua sense resoldre’s, i un resultat negatiu necessita el context familiar abans de poder considerar-se tranquil·litzador.
A prova germinal de BRCA analitza l’ADN, habitualment d’una mostra de sang o saliva al laboratori, en lloc de mesurar la concentració d’una proteïna. El resultat no es pot interpretar com un valor en ng/mL: la informació clínicament útil és el gen, la variant exacta, la classificació i l’abast de les proves.
La majoria de les persones tenen 2 còpies de BRCA1 i 2 còpies de BRCA2, amb una còpia de cadascun heretada de cada progenitor biològic. Un canvi perjudicial en una còpia pot augmentar la predisposició al càncer, però, en general, altres canvis cel·lulars contribueixen al desenvolupament del càncer: l’herència no és un compte enrere fins a la malaltia.
En el cas hipotètic d’una persona de 38 anys sense càncer, un resultat patogènic de BRCA2 pot canviar les converses sobre el cribratge i la prevenció futurs sense establir cap diagnòstic actual de càncer. En el cas d’algú que ja rep tractament contra el càncer, la mateixa troballa hereditària també pot afectar l’elegibilitat per a un tractament i l’avaluació de càncers futurs.
Kantesti és una Analitzador de sang amb IA per a la interpretació rutinària de laboratori, no com a substitut d’un laboratori de genètica clínica. La informació sobre la nostra organització ajuda a distingir la nostra funció educativa de la feina especialitzada necessària per interpretar un resultat de càncer hereditari.
Quins detalls d’un informe de laboratori de BRCA són importants?
Els detalls més útils d’un informe de BRCA són el gen, la variant exacta, la classificació, el tipus de mostra i el mètode de les proves. Els laboratoris clínics solen utilitzar 5 classificacions de variants, i la paraula “variant” per si sola no indica si una troballa és perjudicial.
El marc de l’ACMG/AMP distingeix les troballes patogèniques, probablement patogèniques, de significat incert, probablement benignes i benignes (Richards et al., 2015). Les variants patogèniques i probablement patogèniques solen justificar la mateixa via de gestió clínica; la distinció descriu el grau de certesa de les proves, no dos percentatges diferents de risc de càncer.
Les descripcions de variants poden incloure un canvi a nivell de l’ADN que comença amb c. and a protein-level consequence beginning with p. These are coordinates, not severity scores; two reports may describe the same change differently because they use different transcripts or historical naming conventions.
Look for both sequence analysis i deletion/duplication analysis when evaluating a comprehensive BRCA1/BRCA2 test. Reading individual DNA changes and detecting missing or extra gene segments require complementary methods, so a report stating “sequencing negative” may not answer every relevant question.
A hypothetical report can contain 2 findings: a pathogenic BRCA1 variant and an unrelated BRCA2 VUS. Management follows the established pathogenic finding, not an average of the two classifications; our guide to categorical versus numerical results explains why laboratory result types require different reading strategies.
Significat d’un resultat positiu de BRCA1: predisposició, no certesa
BRCA1 positive meaning depends on the classification: a germline pathogenic or likely pathogenic BRCA1 variant indicates inherited cancer susceptibility. In a prospective study, women carrying pathogenic BRCA1 variants had an estimated 72% breast cancer risk and 44% ovarian cancer risk by age 80.
Kuchenbaecker et al. reported those age-80 estimates in JAMA, with 95% confidence intervals of 65–79% for breast cancer i 36–53% for ovarian cancer (2017). The intervals describe uncertainty around population estimates; they do not mean an individual’s risk can be read directly from the laboratory report.
A hypothetical 30-year-old BRCA1 carrier should not interpret a 72% age-80 estimate as a 72% risk this year. Personal counseling separates near-term risk from longer-term risk and considers age, prior cancer, relatives’ diagnoses and any preventive procedures already completed.
BRCA1-associated breast cancers are more often triple-negative than breast cancers in the general population, but receptor status cannot be predicted from an inherited result alone. An existing cancer still requires its own pathological and receptor assessment; a genetic finding does not replace those separate tests.
One family can also have more than one inherited explanation for cancer, particularly when diagnoses cluster on both parental branches. For example, several colorectal and endometrial cancers may justify a separate assessment of Lynch syndrome results rather than assuming a BRCA1 finding explains every diagnosis.
En què es diferencia el risc de càncer de la mutació BRCA2?
BRCA2 mutation cancer risk includes breast and ovarian cancer susceptibility, with particular relevance to male breast, prostate and pancreatic cancer assessment. In the same prospective JAMA study, women carrying pathogenic BRCA2 variants had estimated risks of 69% for breast cancer and 17% for ovarian cancer by age 80.
The BRCA2 estimates had 95% confidence intervals of 61–77% for breast cancer i 11–25% for ovarian cancer (Kuchenbaecker et al., 2017). BRCA2’s lower average ovarian cancer risk compared with BRCA1 helps explain why preventive ovary-and-tube removal is commonly discussed later for BRCA2 carriers.
A previous breast cancer creates a different risk question: the chance of another cancer in the opposite breast. Kuchenbaecker et al. estimated 20-year contralateral breast cancer risks of 26% for BRCA2 and 40% for BRCA1; those figures are not the same as first-cancer risk and should not be substituted for it.
Prostate screening discussions may begin around age 40 in men with pathogenic BRCA2 variants, depending on the applicable clinical pathway. PSA is a screening measurement rather than a symptom generator; our explanation of what elevated PSA means separates the laboratory number from a diagnosis.
Pancreatic surveillance is another area where eligibility criteria differ, including the importance assigned to family history. A hypothetical 52-year-old BRCA2 carrier with an affected first-degree relative needs a specialist discussion about MRI-based imaging or endoscopic ultrasound—not routine CA 19-9 testing as a substitute.
Què significa una variant de significat incert de BRCA?
A BRCA variant of uncertain significance, or VUS, means available evidence cannot establish whether a DNA change increases cancer risk. A VUS is not a positive result, and it should not independently determine preventive mastectomy or removal of the ovaries and fallopian tubes.
The ACMG/AMP standards state that a VUS no s’ha d’utilitzar en la presa de decisions clíniques (Richards et al., 2015). Among the 5 classification categories, uncertainty is an evidence status—not a diagnosis, not a halfway-positive result and not a 50% probability that the variant causes cancer.
For example, a hypothetical 42-year-old with a BRCA1 VUS and no significant family history should not be offered risk-reducing surgery because of that VUS alone. Another 42-year-old with the same VUS and a substantial family history may qualify for intensified surveillance because of the history, not because the uncertain variant became actionable.
Ancestry can affect how often laboratories encounter uncertainty because population databases do not represent every group equally. Two people with the same cancer history can therefore receive different levels of interpretive certainty; this reflects evidence gaps and does not establish a biological difference in the seriousness of their results.
At Kantesti, we separate finding a genetic change from proving that the change warrants action. The same distinction helps readers understand common MTHFR variant findings, although MTHFR results and BRCA-associated cancer susceptibility have very different clinical implications.
Pot canviar més endavant la classificació d’una VUS de BRCA?
A BRCA VUS can be reclassified when new evidence clarifies its clinical significance. Many reclassified VUS move toward benign categories, but neither the direction nor the timing can be promised for an individual finding; reinterpretation usually reviews existing DNA data rather than requiring another sample.
Useful new evidence can come from 3 broad sources: population frequency, carefully validated functional work and observations of the variant in families. A computer prediction alone is usually insufficient; expert curation weighs whether the evidence actually addresses the disease mechanism and meets classification standards.
Laboratories can disagree because their evidence differs or their interpretations were issued at different times. Record 2 separate dates when available—the original report date and the most recent classification date—and ask whether a specialist expert-panel assessment exists, rather than counting database entries as votes.
Routine testing of unaffected relatives for a VUS usually does not guide care, although a genetics team may arrange selected family studies to help classification. A hypothetical family with 3 affected relatives should not independently order VUS testing for everyone and interpret who carries it as proof of causation.
Ask which laboratory manages reinterpretation, how amended reports reach you and whether your contact details remain current; there is no universal recontact interval. Our discussion of inherited TTR variant interpretation illustrates the broader need to connect exact genetic findings with disease-specific evidence.
Quan és un resultat negatiu de BRCA un veritable negatiu?
A true negative BRCA result means testing did not find the specific pathogenic or likely pathogenic variant already identified in a biological relative. It removes the inherited risk attributable to that familial variant, but it does not eliminate ordinary cancer risk or unrelated risks from the other family branch.
Suppose a hypothetical mother has a confirmed pathogenic BRCA1 variant and her adult daughter’s targeted test excludes that exact variant. Before testing, the daughter generally had a probabilitat d’herència del 50%; afterward, she is not considered a carrier of that maternal finding and cannot pass that uncarried variant to her children.
A negative result becomes less definitive if nobody knows the affected relative’s exact finding. Bring a copy of the original family report rather than a verbal account of “BRCA positive”; a gene name alone cannot distinguish a pathogenic variant from a VUS or identify which change the laboratory should test.
An independently concerning paternal history can remain relevant despite a maternal true negative. For example, 2 close paternal relatives with early breast cancer may warrant separate risk assessment, because excluding one maternal variant does not explain another branch of the pedigree.
The logic of matching a relative’s exact finding also appears in family-based Alport genetic testing, although the genes and inheritance patterns differ. Ask for a written statement identifying which familial variant was excluded and what remaining screening recommendation follows from your own history.
Per què un resultat negatiu de BRCA pot no ser informatiu?
Un negatiu no informatiu means no actionable BRCA finding was detected, but testing has not explained a suspicious personal or family cancer history. The result may reflect another gene, a technical limitation or a familial risk pattern that cannot currently be assigned to one detectable variant.
Testing an affected relative first usually provides more information than testing an unaffected relative. A hypothetical unaffected 35-year-old’s negative panel does not prove that her mother’s ovarian cancer lacked an inherited cause; testing the mother, when possible, can establish whether there is a familial finding to exclude.
A broader panel may consider genes such as PALB2, ATM, CHEK2, RAD51C, RAD51D and BRIP1, depending on the cancer pattern. These genes do not share identical cancer risks or prevention recommendations, so “panel positive” still requires gene-specific interpretation rather than applying the BRCA pathway to every result.
Older tests or limited consumer tests may assess only selected variants, whereas comprehensive clinical testing can include sequencing and deletion/duplication analysis. Our explanation of hidden carrier-screening limitations illustrates why a reassuring-looking result can still depend on methodology, although SMA uses a different genetic model.
Kantesti AI does not establish the completeness of a genetic assay or certify that a family’s inherited risk has been excluded. If a hypothetical family has 3 related cancers despite negative testing, clinical genetics can decide whether updated testing, another affected relative or a formal family-history risk model would answer the unresolved question.
Una troballa de BRCA en un tumor vol dir que és hereditària?
A BRCA variant found in tumor tissue is not automatically inherited. Tumor testing can detect acquired changes confined to cancer cells; germline testing examines a suitable non-tumor specimen to determine whether the finding is constitutional and relevant to relatives.
A tumor report may show a variant allele fraction near 50%, but that number does not prove germline origin. Tumor purity, copy-number changes and loss of the other gene copy can all shift the fraction; a percentage on a tumor report cannot replace a properly selected germline test.
Some oncology reports describe homologous recombination deficiency, or HRD, rather than a specific inherited variant. HRD can arise through more than one mechanism, and an HRD-positive result does not establish that a person or their children carry a pathogenic BRCA1 or BRCA2 variant.
After an allogeneic stem-cell transplant, a blood-derived DNA sample may reflect the donor, and saliva can also contain donor-derived cells. A hypothetical transplant recipient therefore needs the genetics laboratory to select an appropriate specimen—sometimes cultured skin fibroblasts—rather than assuming that 2 easily obtained samples answer the inheritance question.
The distinction between acquired and inherited DNA changes also matters in UBA1-related VEXAS testing, although VEXAS is a different condition. For a tumor BRCA finding, ask whether germline confirmation has been completed, is pending or was never requested.
Quan és més útil l’assessorament genètic?
Genetic counseling helps before testing and whenever a result could change screening, treatment or family testing. It is especially useful for pathogenic findings, unresolved VUS, limited negative tests and family patterns involving young diagnoses, ovarian cancer, male breast cancer or multiple related cancers.
A practical pedigree usually covers 3 generacions and records cancer type, age at diagnosis, biological relationships and both maternal and paternal branches. “Abdominal cancer” is less useful than a confirmed primary site; ovarian, pancreatic and metastatic cancers can otherwise be misremembered as the same diagnosis.
Small families, early deaths and few female relatives can hide hereditary breast-and-ovarian cancer patterns. A hypothetical father with 2 sons and no sisters can carry and transmit a BRCA variant even when the family has no obvious breast cancer cluster; paternal inheritance deserves the same attention as maternal inheritance.
Kantesti és una plataforma d’interpretació d’anàlisi de sang AI, not a genetic counseling service. Our guidance on age-appropriate family testing separates routine laboratory needs from predictive BRCA testing, which is generally deferred in children under 18 because management usually begins in adulthood.
Before an appointment, gather the actual family report, pathology details if available and your previous test methods. Use separate consent for each relative’s records; our discussion of family health consent explains why a shared family history does not give one person automatic permission to access everyone’s medical information.
Quin seguiment cal després d’un resultat patogènic de BRCA?
A germline pathogenic BRCA result warrants a personalized prevention plan, not automatic surgery. Options include enhanced breast screening, discussion of risk-reducing procedures and assessment of other gene-associated cancers; age, reproductive plans, previous cancer and local guidance determine the timing.
Many high-risk pathways use annual breast MRI beginning around ages 25–30, with mammography commonly added around age 30, but national recommendations differ. The reason for combining methods is that each detects some findings the other can miss; more imaging is not simply a substitute for understanding age-specific benefit and false-positive risk.
NICE guideline NG241 lists risk-reducing removal of ovaries and fallopian tubes no earlier than age 35 for BRCA1 and 40 for BRCA2, with individualized assessment (NICE, 2024). Common clinical discussions use windows of approximately 35–40 and 40–45 years, respectively, after childbearing; these are planning ranges, not instructions for every carrier.
Removing only the fallopian tubes while delaying ovary removal has not been established as equivalent protection and remains a trial-based strategy in NICE guidance. Surgical menopause can affect symptoms, cardiovascular health and bones; our guia de salut hormonal de les dones explains why prevention planning includes consequences beyond cancer risk.
Hormone treatment after premenopausal risk-reducing surgery may be considered until the usual menopause age, approximately 51, but previous breast cancer and other contraindications change that discussion. Bone-density assessment and evaluation of secondary bone-loss causes are distinct tasks; our guide to bone health laboratory assessment explains what routine tests can and cannot answer.
Què significa un resultat de BRCA per als familiars i els fills?
Each child of a germline BRCA pathogenic-variant carrier usually has a 50% chance of inheriting the variant, regardless of sex. Adult relatives can consider targeted testing for the established family finding; inheriting susceptibility does not mean inheriting an existing cancer.
Four children do not imply that exactly 2 will inherit a parent’s BRCA variant. Each pregnancy is an independent event, so all, none or any number in between can inherit it; the 50% figure describes probability rather than a guaranteed family distribution.
A carrier’s siblings often have a probabilitat del 50% of sharing the variant when a parent carries it, but that estimate should not be applied without checking the pedigree. Identifying which parent carries the finding helps determine which cousins, aunts and uncles should receive an invitation to discuss testing.
Reproductive options can include natural conception, prenatal diagnosis or IVF with preimplantation genetic testing for a known familial variant. These are preference-sensitive choices, not obligations; our explanation of reproductive genetic result counseling shows why gene-specific inheritance matters, although FMR1 repeat expansion behaves differently from BRCA inheritance.
A rare additional question arises when both partners carry pathogenic variants in mutació BRCA2: each pregnancy has a 25% chance of inheriting pathogenic variants in both copies, which can cause a Fanconi anemia phenotype. Partner testing is not automatically required for every BRCA carrier, but ancestry, relatedness and reproductive planning can justify specialist assessment.
Els símptomes o els marcadors tumorals poden confirmar un càncer relacionat amb BRCA?
Neither a BRCA result nor a tumor-marker concentration confirms that cancer is present. New symptoms need their own assessment, and a negative genetic result does not make them harmless; examination, imaging and sometimes tissue assessment answer a different question from inherited susceptibility testing.
CA-125 can rise in benign conditions and can remain normal in ovarian cancer, particularly earlier disease. Routine CA-125 and ultrasound screening have not demonstrated a mortality benefit sufficient to replace established risk-reduction discussions; our guide to CA-125 limits and symptoms explains why the usual 35 U/mL cutoff is not a cancer yes-or-no boundary.
CA 15-3 and CA 27-29 are not appropriate tests for deciding whether an unaffected BRCA carrier has developed breast cancer. A hypothetical carrier with a normal marker still needs assessment of a new breast lump; our explanation of CA 15-3 interpretation separates selected monitoring uses from screening.
Kantesti does not infer BRCA carrier status from routine laboratory markers. For example, a CA 19-9 result of 80 U/mL can have non-cancer explanations and cannot establish pancreatic cancer or inherited BRCA2 risk; our guide to CA 19-9 limitations explains the need for clinical and imaging context.
Persistent bloating, early satiety, unexplained weight loss, a new breast change or unexplained jaundice deserve timely medical review regardless of genetic classification. A hypothetical person with 3 weeks of new persistent symptoms should not wait for VUS reclassification or a routine genetics appointment before seeking a separate assessment.
Utilitzeu les explicacions de la IA sense substituir l’assessorament genètic
AI explanations can support understanding, but they cannot independently classify a BRCA variant or authorize preventive surgery. A safe workflow preserves 3 essentials: the original laboratory report, specialist interpretation and a written follow-up plan that distinguishes inherited risk from evaluation of any current symptoms.
Kantesti és una plataforma d’interpretació de biomarcadors per IA that explains routine laboratory findings, with interpretation generally available in about 60 seconds. That turnaround is not a timetable for genetic counseling, and our informació sobre la metodologia clínica should not be read as validation of independent BRCA classification or hereditary cancer risk calculation.
Genetic reports can reveal information relevant to more than persona, including biological relatives who have not chosen testing. Read our privadesa i pràctiques de dades before sharing sensitive documents, and avoid uploading another relative’s identifiable report without their permission.
The 2 research publications listed below concern our global routine-test report and RDW educational material; they are not BRCA cancer-risk studies, clinical prevention guidelines or evidence supporting surgery. The medical recommendations in this article instead draw on the ACMG/AMP classification standards, the prospective JAMA risk study and NICE familial ovarian cancer guidance.
Before acting, ask your genetics team to document whether the result is germline, which exact variant is actionable and whether a negative is true or uninformative. Our principis d'IA responsable support keeping those clinical decisions with qualified professionals rather than treating an automated explanation as another laboratory classification.
Preguntes freqüents
Un resultat positiu en una prova de BRCA1 o BRCA2 vol dir que tinc càncer?
Un resultat positiu de la prova germinal de BRCA1 o BRCA2 identifica una variant hereditària patogènica o probablement patogènica; no diagnostica càncer. En l’estudi prospectiu de Kuchenbaecker et al. publicat a JAMA, els riscos estimats de càncer de mama fins als 80 anys eren del 72% per a BRCA1 i del 69% per a BRCA2 en dones portadores de variants patogèniques. Són estimacions poblacionals, no la probabilitat que hi hagi càncer en aquest moment. El diagnòstic d’un càncer actual requereix una avaluació clínica independent.
M'hauria de sotmetre a una cirurgia preventiva per una variant de significat incert del gen BRCA?
Una variant BRCA de significat incert no hauria de determinar per si sola una cirurgia preventiva. El marc de l’ACMG/AMP inclou les VUS entre 5 classificacions basades en l’evidència i estableix que les variants incertes no s’han d’utilitzar per prendre decisions clíniques. Els antecedents personals o familiars poden justificar per separat una atenció de més risc, però aquesta decisió no ha de pressuposar que la VUS és patogènica. Un professional de la genètica pot explicar quines proves avalen realment qualsevol procediment proposat.
Quina diferència hi ha entre un resultat negatiu veritable i un resultat negatiu no informatiu de BRCA?
Un resultat negatiu veritable exclou la variant BRCA patògena o probablement patògena específica que ja s’ha identificat en un familiar biològic. En el cas d’un fill o filla d’una persona portadora, això pot resoldre la probabilitat inicial del 50 % d’haver heretat aquesta variant familiar. Un resultat negatiu no informatiu no detecta cap variant accionable, però no estableix per què s’han produït càncers a la família. Després de qualsevol dels dos resultats, altres branques familiars, gens addicionals i limitacions de les proves poden continuar sent rellevants.
Un VUS de BRCA pot donar positiu més endavant?
Una VUS de BRCA es pot reclassificar posteriorment com a patogènica o probablement patogènica, però també pot passar a considerar-se probablement benigna o benigna. La reclassificació revisa les proves dins del mateix marc de 5 categories; no vol dir que l’ADN de la persona hagi canviat. No hi ha cap termini universal ni cap direcció garantida per a una variant concreta. Pregunteu al laboratori original o al servei de genètica com gestionen els informes modificats i el contacte posterior.
Puc heretar una variant de BRCA del meu pare?
Una variant patògena de BRCA1 o BRCA2 es pot heretar de qualsevol dels dos progenitors biològics. Cada fill d’una persona portadora d’una variant germinal sol tenir un 50% de probabilitats d’heretar-la, tant si la persona portadora és la mare com si és el pare. Una família per part de pare amb poques dones pot tenir pocs antecedents visibles de càncer de mama o d’ovari, tot i ser portadora d’una variant. Per tant, l’assessorament genètic hauria de tenir en compte les dues branques familiars.
Una mutació de BRCA detectada al meu tumor vol dir que els meus fills corren risc?
Una mutació de BRCA detectada al teixit tumoral no demostra que sigui hereditària. Ni tan sols una fracció al·lèlica variant pròxima al 50% al tumor pot demostrar de manera fiable que tingui un origen germinal, perquè la puresa tumoral i els canvis en el nombre de còpies afecten aquest percentatge. Cal fer una prova genètica germinal amb una mostra adequada per determinar si és hereditària. La probabilitat habitual de transmissió del 50% només s’aplica quan el progenitor és portador d’una variant germinal.
He de repetir cada any un resultat negatiu de la prova BRCA?
En general, no cal repetir les proves d’ADN de BRCA cada any, perquè una variant hereditària no apareix simplement amb l’edat. Pot ser convenient revisar un resultat negatiu si l’anàlisi original era limitada, si s’identifica una nova variant familiar o si un altre familiar desenvolupa un càncer rellevant. Per exemple, analitzar només 3 variants seleccionades no equival a fer una seqüenciació completa de BRCA1/BRCA2 més una anàlisi de delecions i duplicacions. Consulteu un servei de genètica per saber si una reinterpretació, les proves familiars dirigides o un altre panell aportarien informació.
Fes que t’expliquin els resultats anàlisi de sang
Puja l’informe del laboratori i la IA de Kantesti t’explicarà cada biomarcador en llenguatge planer en qüestió de segons. Més de 2 milions de persones d’arreu del món ja l’han utilitzat.
Referències
- Klein, T., Mitchell, S., & Weber, H. (2026). Analitzador d’anàlisi de sang amb IA: 2,5M proves analitzades | Global Health Report 2026. Recerca mèdica amb IA de Kantesti. DOI
- Klein, T., Mitchell, S., & Weber, H. (2026). Anàlisi de sang RDW: guia completa sobre RDW-CV, MCV i MCHC. Recerca mèdica amb IA de Kantesti. DOI
- Richards S et al. (2015). Estàndards i directrius per a la interpretació de variants de seqüència: recomanació de consens conjunta de l’American College of Medical Genetics and Genomics i l’Association for Molecular Pathology. Genètica en Medicina. DOI PubMed
- Kuchenbaecker KB et al. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. DOI PubMed
- National Institute for Health and Care Excellence (2024). Ovarian cancer: identifying and managing familial and genetic risk. NICE guideline NG241.
- Més de 2 milionsProves analitzades
- 127+Països
- 100+Idiomes
Sobre l’equip mèdic
Senyals de confiança E-E-A-T
Experiència
Revisió clínica liderada per metges dels fluxos de treball d’interpretació de laboratori.
Experiència
Enfocament en medicina de laboratori sobre com es comporten els biomarcadors en context clínic.
Autoritat
Revisat mèdicament pel Dr. Thomas Klein, amb aportacions de la Dra. Sarah Mitchell i el Prof. Dr. Hans Weber.
Fiabilitat
Interpretació basada en l’evidència amb vies de seguiment clares per reduir l’alarma.
Exempció de responsabilitat mèdica
Aquest article és només per a finalitats educatives i no constitueix assessorament mèdic. Consulteu sempre un professional sanitari qualificat per a decisions de diagnòstic i tractament.
Publicat · Contacteu amb l’equip editorial
Publicat per Kantesti Ltd, registrat a Anglaterra i Gal·les, número de societat. 17090423, Londres, Regne Unit.
